Skip to main content
Top
Published in: Rheumatology International 7/2014

01-07-2014 | Original Article

Thoughts and perceptions of ankylosing spondylitis patients with regard to TNF inhibitors

Authors: Fatma Ilknur Cinar, Muhammet Cinar, Sedat Yilmaz, Ismail Simsek, Hakan Erdem, Salih Pay

Published in: Rheumatology International | Issue 7/2014

Login to get access

Abstract

The risk of infections and malignancies is the major area of concern with anti-tumor necrosis factor (anti-TNF) agents. The aim of this study was to investigate patients’ views about their treatments and the factors that influence patients’ treatment decisions concerning the use of anti-TNF-α drugs. This descriptive study was conducted in a single rheumatology unit. Patients using anti-TNF-α drugs for at least 3 months were included. Patients’ thoughts and perceptions about their treatment were evaluated using a questionnaire. A total of 101 (94.1 % male) patients were recruited. The patients described their feelings as hopeful, worried, happy, scared, desperate, and hopeless, with the order decreasing beginning with the first. Hope for healing and an expectation of increased quality of life were the most significant determinants for acceptance of treatment. After the drug information was given, patients described their feelings as follows: increase in anxiety, psychologically wearisome, and worrying about their condition worsening in the future. After anti-TNF-α treatment, patients described their experience as follows: “the most effective medicine that I have ever used,” “it saved my life,” “control procedures that were carried out before the treatment and once every 3 months after the treatment were essential,” “I feel myself safe with these controls,” and “I advised other people.” This study, to our knowledge, is the first to evaluate the attitudes of patients concerning anti-TNF-α drugs from the stage of informed consent to the post-experience stage. We found that standard consent forms caused an increase in the level of anxiety among new users of anti-TNF-α drugs, although the aim was the exact opposite. The reasons for acceptance were the hope for healing, reliance on physicians, and advice of other patients. Most patients accepted follow-up control procedures, which aimed to diagnose adverse effects early.
Literature
1.
go back to reference Farren W, Goodacre L, Stigant M (2013) Fatigue in ankylosing spondylitis: causes, consequences and self-management. Musculoskelet Care 11:39–50CrossRef Farren W, Goodacre L, Stigant M (2013) Fatigue in ankylosing spondylitis: causes, consequences and self-management. Musculoskelet Care 11:39–50CrossRef
2.
go back to reference Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O’Connor P, Tan AL, Conaghan PG, Greenstein A, Emery P (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64:1568–1575PubMedCentralPubMedCrossRef Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O’Connor P, Tan AL, Conaghan PG, Greenstein A, Emery P (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64:1568–1575PubMedCentralPubMedCrossRef
3.
go back to reference Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, Calguneri M, Kalyoncu U (2012) Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int 32:323–330PubMedCrossRef Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, Calguneri M, Kalyoncu U (2012) Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int 32:323–330PubMedCrossRef
4.
go back to reference Stockdale J, Goodacre L (2009) ‘It’s magic stuff’: the experiences of patients with ankylosing spondylitis taking anti-TNF-alpha medication. Musculoskelet Care 7:162–177CrossRef Stockdale J, Goodacre L (2009) ‘It’s magic stuff’: the experiences of patients with ankylosing spondylitis taking anti-TNF-alpha medication. Musculoskelet Care 7:162–177CrossRef
5.
go back to reference Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G, Krause A, Bohl-Buhler M, Freundlich B, Rudwaleit M et al (2011) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 70:590–596PubMedCentralPubMedCrossRef Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G, Krause A, Bohl-Buhler M, Freundlich B, Rudwaleit M et al (2011) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 70:590–596PubMedCentralPubMedCrossRef
6.
go back to reference Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-De-Prati R, Kupper H, Kary S (2009) Effectiveness, safety, and predictors of good clinical response in 1,250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36:801–808PubMedCrossRef Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-De-Prati R, Kupper H, Kary S (2009) Effectiveness, safety, and predictors of good clinical response in 1,250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36:801–808PubMedCrossRef
7.
go back to reference Barkham N, Keen HI, Coates LC, O’Connor P, Hensor E, Fraser AD, Cawkwell LS, Bennett A, McGonagle D, Emery P (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthr Rheum 60:946–954CrossRef Barkham N, Keen HI, Coates LC, O’Connor P, Hensor E, Fraser AD, Cawkwell LS, Bennett A, McGonagle D, Emery P (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthr Rheum 60:946–954CrossRef
8.
go back to reference Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64:229–234PubMedCentralPubMedCrossRef Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64:229–234PubMedCentralPubMedCrossRef
9.
go back to reference Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824PubMedCentralPubMedCrossRef Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824PubMedCentralPubMedCrossRef
10.
go back to reference Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmarti R, Sany J, van der Linden S, Veys E, Appel AM, Fatenejad S (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594–1600PubMedCentralPubMedCrossRef Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmarti R, Sany J, van der Linden S, Veys E, Appel AM, Fatenejad S (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594–1600PubMedCentralPubMedCrossRef
11.
go back to reference Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA (2005) Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 64(6):940–942PubMedCentralPubMedCrossRef Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA (2005) Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 64(6):940–942PubMedCentralPubMedCrossRef
12.
go back to reference van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthr Rheum 52:582–591CrossRef van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthr Rheum 52:582–591CrossRef
13.
go back to reference Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthr Rheum 56:1433–1439CrossRef Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthr Rheum 56:1433–1439CrossRef
14.
go back to reference Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthr Rheum 56:2886–2895CrossRef Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthr Rheum 56:2886–2895CrossRef
15.
go back to reference Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265PubMedCrossRef Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265PubMedCrossRef
16.
go back to reference Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA (2006) Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford) 45:1288–1293CrossRef Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA (2006) Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford) 45:1288–1293CrossRef
17.
go back to reference Baysal O, Durmus B, Ersoy Y, Altay Z, Senel K, Nas K, Ugur M, Kaya A, Gur A, Erdal A, Ardıçoğlu O, Tekeoğlu I, Cevik R, Yıldırım K, Kamanlı A, Saraç AJ, Karatay S, Ozgocmen S (2011) Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. Rheum Int 31:795–800CrossRef Baysal O, Durmus B, Ersoy Y, Altay Z, Senel K, Nas K, Ugur M, Kaya A, Gur A, Erdal A, Ardıçoğlu O, Tekeoğlu I, Cevik R, Yıldırım K, Kamanlı A, Saraç AJ, Karatay S, Ozgocmen S (2011) Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. Rheum Int 31:795–800CrossRef
18.
go back to reference Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F (2003) Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthr Rheum 49:483–487CrossRef Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F (2003) Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthr Rheum 49:483–487CrossRef
19.
go back to reference Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A (2008) Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J 10:277–281PubMed Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A (2008) Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J 10:277–281PubMed
20.
go back to reference van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthr Rheum 27:361–368CrossRef van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthr Rheum 27:361–368CrossRef
21.
go back to reference Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheum 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheum 21:2286–2291PubMed
22.
go back to reference Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheum 21:2281–2285PubMed Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheum 21:2281–2285PubMed
23.
go back to reference Edwards J (2004) An exploration of patients’ experiences of anti-TNF therapy. Musculoskelet Care 2:40–50CrossRef Edwards J (2004) An exploration of patients’ experiences of anti-TNF therapy. Musculoskelet Care 2:40–50CrossRef
24.
go back to reference Sanderson T, Calnan M, Morris M, Richards P, Hewlett S (2009) The impact of patient-perceived restricted access to anti-TNF therapy for rheumatoid arthritis: a qualitative study. Musculoskelet Care 7:194–209CrossRef Sanderson T, Calnan M, Morris M, Richards P, Hewlett S (2009) The impact of patient-perceived restricted access to anti-TNF therapy for rheumatoid arthritis: a qualitative study. Musculoskelet Care 7:194–209CrossRef
25.
26.
go back to reference Frich LM (2003) Nursing interventions for patients with chronic conditions. J Adv Nurs 44:137–153PubMedCrossRef Frich LM (2003) Nursing interventions for patients with chronic conditions. J Adv Nurs 44:137–153PubMedCrossRef
27.
go back to reference Pehlivan S, Ovayolu Ö, Ovayolu N, Pehlivan Y, Onat AM (2010) Romatolojik sorunu olan hastalarda yaşam kalitesi ve bazı semptomlarla ilişkisi. Gaziantep Med J 16:10–14 Pehlivan S, Ovayolu Ö, Ovayolu N, Pehlivan Y, Onat AM (2010) Romatolojik sorunu olan hastalarda yaşam kalitesi ve bazı semptomlarla ilişkisi. Gaziantep Med J 16:10–14
28.
go back to reference Eckman MH, Wise R, Leonard AC, Dixon E, Burrows C, Khan F, Warm E (2012) Impact of health literacy on outcomes and effectiveness of an educational intervention in patients with chronic diseases. Patient Educ Couns 87:143–151PubMedCrossRef Eckman MH, Wise R, Leonard AC, Dixon E, Burrows C, Khan F, Warm E (2012) Impact of health literacy on outcomes and effectiveness of an educational intervention in patients with chronic diseases. Patient Educ Couns 87:143–151PubMedCrossRef
29.
go back to reference Nair K, Dolovich L, Cassels A, McCormack J, Levine M, Gray J, Mann K, Burns S (2002) What patients want to know about their medications. Focus group study of patient and clinician perspectives. Can Fam Physician 48:104–110PubMedCentralPubMed Nair K, Dolovich L, Cassels A, McCormack J, Levine M, Gray J, Mann K, Burns S (2002) What patients want to know about their medications. Focus group study of patient and clinician perspectives. Can Fam Physician 48:104–110PubMedCentralPubMed
30.
go back to reference Cinar FI, Tosun N, Akbayrak N, Simsek I, Cinar M, Erdem H, Pay S, Kilic S, Yilmaz S, Cetinkaya S, Dinc A (2013) Comparison of the efficacy of written information vs. verbal plus written information in rheumatic patients who receive colchicine treatment. Gulhane Med J 55:94–100CrossRef Cinar FI, Tosun N, Akbayrak N, Simsek I, Cinar M, Erdem H, Pay S, Kilic S, Yilmaz S, Cetinkaya S, Dinc A (2013) Comparison of the efficacy of written information vs. verbal plus written information in rheumatic patients who receive colchicine treatment. Gulhane Med J 55:94–100CrossRef
31.
go back to reference Suarez-Almazor ME, Kendall CJ, Dorgan M (2001) Surfing the Net–information on the World Wide Web for persons with arthritis: patient empowerment or patient deceit? J Rheumatol 28:185–191PubMed Suarez-Almazor ME, Kendall CJ, Dorgan M (2001) Surfing the Net–information on the World Wide Web for persons with arthritis: patient empowerment or patient deceit? J Rheumatol 28:185–191PubMed
32.
go back to reference Dagfinrud H, Vollestad NK, Loge JH, Kvien TK, Mengshoel AM (2005) Fatigue in patients with ankylosing spondylitis: A comparison with the general population and associations with clinical and self-reported measures. Arthr Rheum 53:5–11CrossRef Dagfinrud H, Vollestad NK, Loge JH, Kvien TK, Mengshoel AM (2005) Fatigue in patients with ankylosing spondylitis: A comparison with the general population and associations with clinical and self-reported measures. Arthr Rheum 53:5–11CrossRef
33.
go back to reference Gunal EK, Sarvan FO, Kamali S, Gul A, Inanc M, Carin M, Konice M, Aral O, Ocal L (2008) Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Jt Bone Spine 75:299–302CrossRef Gunal EK, Sarvan FO, Kamali S, Gul A, Inanc M, Carin M, Konice M, Aral O, Ocal L (2008) Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Jt Bone Spine 75:299–302CrossRef
34.
go back to reference Cinar M, Akar H, Yilmaz S, Simsek I, Karkucak M, Sagkan RI, Pekel A, Erdem H, Avci IY, Acikel C, Musabak U, Tunca Y, Pay S (2013) A polymorphism in ERAP1 is associated with susceptibility to ankylosing spondylitis in a Turkish population. Rheumatol Int 33:2851–2858PubMedCrossRef Cinar M, Akar H, Yilmaz S, Simsek I, Karkucak M, Sagkan RI, Pekel A, Erdem H, Avci IY, Acikel C, Musabak U, Tunca Y, Pay S (2013) A polymorphism in ERAP1 is associated with susceptibility to ankylosing spondylitis in a Turkish population. Rheumatol Int 33:2851–2858PubMedCrossRef
Metadata
Title
Thoughts and perceptions of ankylosing spondylitis patients with regard to TNF inhibitors
Authors
Fatma Ilknur Cinar
Muhammet Cinar
Sedat Yilmaz
Ismail Simsek
Hakan Erdem
Salih Pay
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 7/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2931-9

Other articles of this Issue 7/2014

Rheumatology International 7/2014 Go to the issue